Search research articles
Contact Us
Filters
Showing results (71-80 of 85) with videos related to
Page
of 9
Sort By:
Scientific Reports
|
August 26, 2024
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study
Mimma Rizzo, Andrey Soares, Enrique Grande, et al.
Targeted Oncology
|
September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII
|
May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Matteo Santoni, Zin W Myint, Thomas Büttner, et al.
European Urology Oncology
|
November 29, 2024
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study
Matteo Santoni, Thomas Büttner, Pasquale Rescigno, et al.
Cancers
|
January 8, 2020
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
Matteo Santoni, Daniel Y Heng, Sergio Bracarda, et al.
Targeted Oncology
|
October 1, 2024
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> Study
Ondřej Fiala, Francesco Massari, Umberto Basso, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2020
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study
Olga Nigro, Graziella Pinotti, Federica De Galitiis, et al.
Clinical Genitourinary Cancer
|
April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Targeted Oncology
|
June 27, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Minerva Urology and Nephrology
|
August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Camillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 85) with videos related to
Sort By:
Page
of 9
Scientific Reports
|
August 26, 2024
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study
Mimma Rizzo, Andrey Soares, Enrique Grande, et al.
Targeted Oncology
|
September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII
|
May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Matteo Santoni, Zin W Myint, Thomas Büttner, et al.
European Urology Oncology
|
November 29, 2024
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study
Matteo Santoni, Thomas Büttner, Pasquale Rescigno, et al.
Cancers
|
January 8, 2020
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
Matteo Santoni, Daniel Y Heng, Sergio Bracarda, et al.
Targeted Oncology
|
October 1, 2024
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> Study
Ondřej Fiala, Francesco Massari, Umberto Basso, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2020
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study
Olga Nigro, Graziella Pinotti, Federica De Galitiis, et al.
Clinical Genitourinary Cancer
|
April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Targeted Oncology
|
June 27, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Minerva Urology and Nephrology
|
August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Camillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.
Page
of 9